Maxime Dely: How Long Can Europe Rely on U.S. Plasma
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The core issue is clear: American Dependence: How long can Europe rely on U.S. Plasma?
In 2024, nearly 70 % of the world’s plasma used to produce plasma-derived medicinal products came from the United States. A figure that clearly shows how vulnerable Europe remains in a domain essential to patient care.
The U.S. collects around 50 million liters of plasma each year, enabled by a highly industrialized model, a dense network of donation centers, and financial compensation for donors.
By contrast, Europe collects only about 9 million liters, mostly concentrated in Austria, Germany, Hungary, and the Czech Republic. The rest of the continent remains largely dependent on imports.
Since 2023, global demand has been rising quickly (+ 12 to + 14%), driven by increased needs for immunoglobulins. But European collection is growing too slowly to close the gap.
To strengthen supply security, Europe has launched several initiatives:
▪️ EU4Health and resilience programs,
▪️ Investments to modernize collection infrastructures,
▪️ Efforts to increase voluntary non-remunerated donations,
▪️ Expansion of local fractionation capacity.
These initiatives represent real progress, but they come after years of structural dependence. Achieving European plasma sovereignty will require coordinated, long-term, and ambitious action.
The core issue is clear: ensuring continuous and secure access to plasma-derived medicines for all European patients.
In your review, what should be the top priority to rebalance this dependency?
Boosting collection? Rethinking the model? Investing in local production?”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis